Shervin Bahrami

Health Technology

Profile

Shervin Bahrami is associated with EnFutech ApS and iSD.
Immunotech ApS.
He was the Chief Executive Officer & Director of EnFutech ApS in 2007 and the Chief Executive Officer of iSD Immunotech ApS from 2007 to 2015.
Dr. Bahrami is the founder of both companies, EnFutech ApS in 2007 and iSD Immunotech ApS in 2007.

Former positions of Shervin Bahrami

Companies	Position	End
iSD Immunotech ApS iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark.	Chief Executive Officer	01/09/2015
EnFutech ApS EnFutech ApS BiotechnologyHealth Technology EnFutech ApS is a holding company that develops technologies for prevention, treatment, and eradication of Human Immunodeficiency Virus (HIV). Its platforms include both a new type of inhibitor that can be used as a prophylactic agent as well as a traditional drug for treatment of infection and a gene therapeutical approach to rendering the T-cells immune to HIV infection. The firm aims to combat infection, by developing effective anti-HIV treatments that can remove the virus both before and after it infects human cells. Its treatment is based on its novel technologies of blocking the HIV co-receptors using retargeted envelope proteins and receptor interference. The company was founded by Finn Skou Pedersen and Martin Tolstrup on August 23, 2007 and is headquartered in Aarhus, Denmark.	Founder	-

See the detail of Shervin Bahrami's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Shervin Bahrami's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
EnFutech ApS EnFutech ApS BiotechnologyHealth Technology EnFutech ApS is a holding company that develops technologies for prevention, treatment, and eradication of Human Immunodeficiency Virus (HIV). Its platforms include both a new type of inhibitor that can be used as a prophylactic agent as well as a traditional drug for treatment of infection and a gene therapeutical approach to rendering the T-cells immune to HIV infection. The firm aims to combat infection, by developing effective anti-HIV treatments that can remove the virus both before and after it infects human cells. Its treatment is based on its novel technologies of blocking the HIV co-receptors using retargeted envelope proteins and receptor interference. The company was founded by Finn Skou Pedersen and Martin Tolstrup on August 23, 2007 and is headquartered in Aarhus, Denmark.	Health Technology
iSD Immunotech ApS iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark.	Health Technology